SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (9)8/27/2002 6:52:04 PM
From: Tim Davies  Read Replies (1) | Respond to of 3722
 
does ctic fit.. there new ovarian anti cancer tests seem to be going well and have recently done a jv with the anderson center.. chart looks nice.. but thats what i thought about aklm this am
tim



To: Jibacoa who wrote (9)8/28/2002 12:57:42 PM
From: Jibacoa  Respond to of 3722
 
GENR Is up 17.33%, which is pretty good under present market conditions.

The stock is up 60% from its low last week (Aug.20) at $0.55.

It has announced the start of a Phase 1-2 trial to test squalamine for the treatment of the "wet", age-related macular degeneration (AMD).

siliconinvestor.com

siliconinvestor.com

Bernard